In spite of efforts, blood transfusion is still accompanied with adverse effects such as transfusion-related immunomodulation (TRIM). The current study aimed to evaluate the effects of allogeneic, syngeneic, fresh and storage blood transfusion on the growth and metastasis of tumors and survival in fibrosarcoma bearing BALB/c mice. Twenty-five BALB/c mice were grouped into five groups of equal size. All groups were injected 1.2 × 106 WEHI-164 cells subcutaneously to induce fibrosarcoma tumor. After expansion of the tumor, in four groups (except for the control group), hemorrhage-induced anemia was developed. Twenty-four hours later, blood deficit was replaced by fresh allogeneic, storage allogeneic, fresh syngeneic and storage syngeneic blood transfusion, respectively. After a blood transfusion, for 13 days, the tumor size and survival of the mice were evaluated. In the day 20, the mice were sacrificed and their spleen tissues were evaluated for TRIM induced metastasis. Tumor size increase in the groups that received allogeneic (fresh and storage) and storage syngeneic blood transfusion was significantly higher than the control group (P value < 0.05). However, no significant difference was present in survival between the experiment groups and the control group. There was no metastasis in none of groups at the end of the study. Allogeneic and storage blood transfusion could have immunomodulatory effects such as increased tumor size. However, it seems that fresh and syngeneic blood transfusion have no effects on tumor growth in fibrosarcoma bearing mice. Further evidence may prove that more attention is warranted in blood transfusion into cancer cases.
Blood transfusion Fibrosarcoma Immunomodulation
This is a preview of subscription content, log in to check access.
The authors would like to thank Hasan Mohammad HosseiniAkbari for his help in histopathological examinations.
AAP and ZMH and KA designed the study. KA performed laboratory works. KA and TM and TJK performed the statistical analysis and wrote the manuscript. All authors read and approved the final manuscript.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights
All procedures performed in studies involving animals were in accordance with the ethical standards of the Tarbiat Modares University.
Bilgin Y, Van de Watering L, Brand A (2011) Clinical effects of leucoreduction of blood transfusions. Neth J Med 69(10):441–450PubMedGoogle Scholar
Rice TC, Pugh AM, Caldwell CC, Schneider BSP (2017) Balance between the proinflammatory and anti-inflammatory immune responses with blood transfusion in sepsis. Crit Care Nurs Clin North Am 29(3):331–340CrossRefPubMedPubMedCentralGoogle Scholar
Dzik S (2000) Mechanisms underlying the immunomodulatory effect of allogeneic blood transfusion. Scientific basis of transfusion medicine: implications for clinical practice, 2nd edn. WB Saunders Company, Philadelphia, pp 444–454Google Scholar
Pereira A (2001) Deleterious consequences of allogeneic blood transfusion on postoperative infection: really a transfusion-related immunomodulation effect? Blood 98(2):498–500CrossRefPubMedGoogle Scholar
Salvatierra O Jr, Vincenti F, Amend W, Potter D, Iwaki Y, Opelz G et al (1980) Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg 192(4):543CrossRefPubMedPubMedCentralGoogle Scholar
Alexander JW, Babcock GF, First MR, Davies CB, Madden RL, Munda R et al (1992) The induction of immunologic hypresponsiveness by preoperative donor-specific transfusions and cyclosporine in human cadaveric transplants. Transplantation 53(2):423–427CrossRefPubMedGoogle Scholar
Lapierre V, Aupérin A, Tiberghien P (1998) Transfusion-induced immunomodulation following cancer surgery: fact or fiction? JNCI J Natl Cancer Inst 90(8):573–580CrossRefPubMedGoogle Scholar
Hellings S, Blajchman MA (2009) Transfusion-related immunosuppression. Anaesth Intensive Care Med 10(5):231–234CrossRefGoogle Scholar
Clark DA, Gorczynski RM, Blajchman MA (2008) Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen. Transfusion 48(5):814–821CrossRefPubMedGoogle Scholar
Blumberg N, Heal JM (1994) Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med 118(4):371–379PubMedGoogle Scholar
Heiss MM, Mempel W, Delanoff C, Jauch K-W, Gabka C, Mempel M et al (1994) Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 12(9):1859–1867CrossRefPubMedGoogle Scholar
Meng J, Lu X-B, Tang Y-X, Sun G-P, Li X, Yan Y-F et al (2013) Effects of allogeneic blood transfusion in patients with stage II colon cancer. Asian Pac J Cancer Prev 14(1):347–350CrossRefPubMedGoogle Scholar
Benson D, Barnett CC (2011) Perioperative blood transfusions promote pancreas cancer progression. J Surg Res 166(2):275–279CrossRefPubMedGoogle Scholar
Bordin J, Bardossy L, Blajchman M (1994) Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion. Blood 84(1):344–348PubMedGoogle Scholar
Hashemi SM, Hassan ZM, Soudi S, Ghazanfari T, Kheirandish M, Shahabi S (2007) Evaluation of anti-tumor effects of tumor cell lysate enriched by HSP-70 against fibrosarcoma tumor in BALB/c mice. Int Immunopharmacol 7(7):920–927CrossRefPubMedGoogle Scholar
Muszynski JA, Spinella PC, Cholette JM, Acker JP, Hall MW, Juffermans NP et al (2017) Transfusion-related immunomodulation: review of the literature and implications for pediatric critical illness. Transfusion 57(1):195–206CrossRefPubMedGoogle Scholar
Atzil S, Arad M, Glasner A, Abiri N, Avraham R, Greenfeld K et al (2008) Blood transfusion promotes cancer progression: a critical role for aged erythrocytes. Anesthesiology 109(6):989–997CrossRefPubMedPubMedCentralGoogle Scholar
Ames S, Shelby J, Roberts L, Nelson E (eds) (1988) Factors in transfusion-related enhanced tumor growth. In: Transplantation proceedings. Elsevier, AtlantaGoogle Scholar
Newman E, Ho M, Heslin MJ, Chapman DS, Brennan MF (1996) The effect of blood transfusion on tumor growth in sarcoma-bearing rats. Ann Surg Oncol 3(1):74–79CrossRefPubMedGoogle Scholar
Dzik S, Aubuchon J, Jeffries L, Kleinman S, Manno C, Murphy MF et al (2000) Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev 14(1):34–52CrossRefPubMedGoogle Scholar
Dent L, Finlay-Jones J (1985) In vivo detection and partial characterization of effector and suppressor cell populations in spleens of mice with large metastatic fibrosarcomas. Br J Cancer 51(4):533CrossRefPubMedPubMedCentralGoogle Scholar
Safford S, Oberley T, Urano M, Clair DS (1994) Suppression of fibrosarcoma metastasis by elevated expression of manganese superoxide dismutase. Can Res 54(16):4261–4265Google Scholar
English WR, Lunt SJ, Fisher M, Lefley DV, Dhingra M, Lee Y-C et al (2017) Differential expression of VEGFA isoforms regulates metastasis and response to anti-VEGFA therapy in sarcoma. Can Res 77(10):2633–2646CrossRefGoogle Scholar